Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 1,534 | 1,558 | 1,363 | 285 | 0 |
| Gross Profit | 1,534 | 1,558 | 1,363 | 285 | N/A |
| Operating Expenses | 97,882 | 68,678 | 57,669 | 43,900 | 22,209 |
| Operating Income | -96,348 | -67,120 | -56,306 | -43,615 | -22,209 |
| Other Income | 2,952 | 4,499 | 1,041 | 102 | 82 |
| Pre-tax Income | -93,396 | -62,621 | -55,265 | -43,513 | -22,127 |
| Income Tax | 39 | 59 | 13 | N/A | N/A |
| Net Income Continuous | -93,435 | -62,680 | -55,278 | -43,513 | -22,127 |
| Net Income | $-93,435 | $-62,680 | $-55,278 | $-43,513 | $-22,127 |
| EPS Basic Total Ops | -71.50 | -63.00 | -91.50 | -167.50 | -129.50 |
| EPS Basic Continuous Ops | -71.75 | -62.93 | -91.41 | -167.54 | -128.80 |
| EPS Diluted Total Ops | -71.50 | -63.00 | -91.50 | -167.50 | -129.50 |
| EPS Diluted Continuous Ops | -71.75 | -62.93 | -91.41 | -167.54 | -128.80 |
| EPS Diluted Before Non-Recurring Items | -49.00 | -61.50 | -91.50 | -167.50 | -129.50 |
| EBITDA(a) | $-98,153 | $-70,338 | $-55,731 | $-42,614 | $-22,114 |